Taysha Gene Therapies Inc. (TSHA)
NASDAQ · Healthcare
Taysha Gene Therapies Inc. Operating Income 2022–2025
Taysha Gene Therapies Inc. annual/quarterly operating income history and growth rate from 2022 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Taysha Gene Therapies Inc. operating income for the quarter ending March 31, 2026 was -43.5 M, a 103.01% increase year-over-year.
- Taysha Gene Therapies Inc. operating income for the twelve months ending March 31, 2026 was -125.7 M, a 43.19% increase year-over-year.
- Taysha Gene Therapies Inc. annual operating income for 2025 was -110.5 M, a 20.82% increase from 2024.
- Taysha Gene Therapies Inc. annual operating income for 2024 was -91.5 M, a 26.26% increase from 2023.
- Taysha Gene Therapies Inc. annual operating income for 2023 was -72.4 M, a 55.41% decrease from 2022.
- Taysha Gene Therapies Inc. annual operating income for 2022 was -162.4 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Taysha Gene Therapies Inc. Operating Income — FAQ
Taysha Gene Therapies Inc. (TSHA) operating income over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
What is Taysha Gene Therapies Inc.'s operating income?
Taysha Gene Therapies Inc. (TSHA) reported operating income of -$110M for fiscal 2025.
Where can I see TSHA's operating income history?
The chart and table above show Taysha Gene Therapies Inc.'s operating income by year and by quarter, including the growth rate.